JP2023514188A - 抗がん剤としてのキヌクリジノン系化合物の応用 - Google Patents

抗がん剤としてのキヌクリジノン系化合物の応用 Download PDF

Info

Publication number
JP2023514188A
JP2023514188A JP2022548528A JP2022548528A JP2023514188A JP 2023514188 A JP2023514188 A JP 2023514188A JP 2022548528 A JP2022548528 A JP 2022548528A JP 2022548528 A JP2022548528 A JP 2022548528A JP 2023514188 A JP2023514188 A JP 2023514188A
Authority
JP
Japan
Prior art keywords
methoxymethyl
hydroxymethyl
methyl
quinuclidin
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2022548528A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023514188A5 (https=
Inventor
チェン,イ
Original Assignee
ニューウェーブ・ファーマスーティカル・インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ニューウェーブ・ファーマスーティカル・インコーポレイテッド filed Critical ニューウェーブ・ファーマスーティカル・インコーポレイテッド
Publication of JP2023514188A publication Critical patent/JP2023514188A/ja
Publication of JP2023514188A5 publication Critical patent/JP2023514188A5/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D453/00Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07Optical isomers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2022548528A 2020-02-09 2021-02-05 抗がん剤としてのキヌクリジノン系化合物の応用 Withdrawn JP2023514188A (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US202062972002P 2020-02-09 2020-02-09
US62/972,002 2020-02-09
US202063002106P 2020-03-30 2020-03-30
US63/002,106 2020-03-30
US202063019374P 2020-05-03 2020-05-03
US63/019,374 2020-05-03
US202063053592P 2020-07-18 2020-07-18
US63/053,592 2020-07-18
PCT/US2021/016862 WO2021158948A1 (en) 2020-02-09 2021-02-05 Quinuclidinone analogues as anticancer agents

Publications (2)

Publication Number Publication Date
JP2023514188A true JP2023514188A (ja) 2023-04-05
JP2023514188A5 JP2023514188A5 (https=) 2024-02-14

Family

ID=74860395

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022548528A Withdrawn JP2023514188A (ja) 2020-02-09 2021-02-05 抗がん剤としてのキヌクリジノン系化合物の応用

Country Status (5)

Country Link
US (1) US20230089530A1 (https=)
EP (1) EP4100407A1 (https=)
JP (1) JP2023514188A (https=)
CN (1) CN116034107A (https=)
WO (1) WO2021158948A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022175402A1 (en) * 2021-02-18 2022-08-25 Aprea Therapeutics Ab Quinuclidine-3-one derivatives
PY2217419A (es) 2021-03-15 2022-09-27 Novartis Ag Derivados de pirazolopiridina y sus usos
WO2022204109A1 (en) * 2021-03-22 2022-09-29 Newave Pharmaceutical Inc. Quinuclidinone analogues as anticancer agents

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
PL2525796T3 (pl) * 2010-01-21 2016-09-30 Wodny roztwór zawierający 3 chinuklidynony do leczenia choroby hiperproliferacyjnej, autoimmunologicznej i serca
CN104860994A (zh) * 2014-02-20 2015-08-26 中国药科大学 3-奎宁环酮类含磷化合物的制备及其医药用途

Also Published As

Publication number Publication date
EP4100407A1 (en) 2022-12-14
CN116034107A (zh) 2023-04-28
US20230089530A1 (en) 2023-03-23
WO2021158948A1 (en) 2021-08-12

Similar Documents

Publication Publication Date Title
US12569564B2 (en) Spirocyclic MDM2 modulator and uses thereof
WO2022271823A1 (en) Mutant kras modulators and uses thereof
US11993610B2 (en) BCL-2 inhibitors
JP7235338B2 (ja) Atr阻害剤としての置換ピロロピリジン
WO2023137223A1 (en) Pan-kras inhibitors and uses thereof
WO2025059040A1 (en) Mutant kras modulators and uses thereof
JP2023514188A (ja) 抗がん剤としてのキヌクリジノン系化合物の応用
US20240058457A1 (en) Btk degrader
US20250136620A1 (en) Btk degrader
US20250099481A1 (en) Bcl-2 inhibitors
US12552784B2 (en) 1H-pyrrolo[2,3-b]pyridine derivatives as BCL-2 inhibitors for the treatment of neoplastic and autoimmune diseases
WO2023076167A1 (en) Inhibitor of btk and mutants thereof
US20240217964A1 (en) Quinuclidinone analogues as anticancer agents
WO2023230059A1 (en) Mdm2 degrader
US20250145639A1 (en) Mutant kras modulators and uses thereof
WO2023283130A1 (en) Isoquinoline derivatives as mutant egfr modulators and uses thereof
HK40097437A (en) Condensed heterocyclic derivatives as bcl-2 inhibitors for the treatment of neoplastic diseases
HK40033360B (en) Condensed heterocyclic derivatives as bcl-2 inhibitors for the treatment of neoplastic diseases
HK40033360A (en) Condensed heterocyclic derivatives as bcl-2 inhibitors for the treatment of neoplastic diseases

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240205

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240205

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20241212

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20250212